SCHEMBL23012175

SCHEMBL23012175

CC(=O)Nc1ccc2oc(-c3ccnc(C(=O)O)c3)nc2c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 9/20 0.70
▸ RAB9A P51151 9/20 0.70
▸ ALDH1A1 P00352 9/20 0.70
▸ KDM4E B2RXH2 6/20 0.70
▸ POLB P06746 6/20 0.70
▸ SMN1; SMN2 Q16637 5/20 0.70
▸ UTRN P46939 1/20 0.65
▸ MAPT P10636 4/20 0.60
▸ CASP3 P42574 3/20 0.58
▸ SENP7 Q9BQF6 3/20 0.58
▸ TDP1 Q9NUW8 2/20 0.58
▸ SENP8 Q96LD8 2/20 0.57
▸ SENP6 Q9GZR1 2/20 0.57
▸ MEN1 O00255 1/20 0.56
▸ KMT2A Q03164 1/20 0.56
▸ HPGD P15428 6/20 0.56
▸ HSD17B10 Q99714 6/20 0.56
▸ NFKB1 P19838 2/20 0.56
▸ NFKB2 Q00653 2/20 0.56
▸ RELA Q04206 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29479597 1.00 NPC1 (0.70) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL23033959 0.91 CASP3 (0.70) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL23034143 0.89 MAPT (0.71) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL28701684 0.88 ALDH1A1 (0.71) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL31165944 0.88 KDM4E (0.67) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL23034137 0.86 NPC1 (0.67) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL23033530 0.86 ALDH1A1 (0.52) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL23012925 0.85 ALDH1A1 (0.61) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL23033325 0.85 ALDH1A1 (0.51) NPC1RAB9AALDH1A1KDM4EPOLB
SCHEMBL29479804 0.85 ALDH1A1 (0.61) NPC1RAB9AALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230079045-A1 ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) 2023-03-16 — — US disclosed
CN-114269725-A Anti-influenza virus compound and preparation method and application thereof 四川海思科制药有限公司 2022-04-01 — — CN disclosed
WO-2021032209-A1 ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF 四川海思科制药有限公司 2021-02-25 — — WO disclosed
WO-2021032209-A1 ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF 四川海思科制药有限公司 2021-02-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230079045-A1 ANTI-INFLUENZA VIRUS COMPOUND, PREPARATION METHOD AND USE THEREOF IDE, ACE, SI NPC1 1194/4885RAB9A 385/4885ALDH1A1 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback